Medicines Co. Stock
-
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
Cons
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 1.720% | -4.344% | 17.387% | 13.622% | -13.241% | -5.710% | -28.139% |
| Opko Health Inc. | -1.500% | 3.150% | 9.167% | 17.573% | 20.161% | -31.103% | -62.182% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 4.400% | 4.403% | -1.190% | -11.230% | -15.306% | -38.060% | -36.641% |
Comments
News
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Most clinical-stage biotechs are small-cap companies. That makes sense. Not only can it take years -- sometimes over a decade -- to develop novel medicines, but it is also a very risky endeavor
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
The June 10 IPO of Parabilis Medicines (NASDAQ: PBLS) closed up 58% from its $20 offer price. Two days later, Space Exploration Technologies, the largest IPO in history, finished its debut up just
Why Eli Lilly Stock Jumped to a New All-Time High Today
Shares of Eli Lilly (NYSE: LLY) climbed to a record high on Friday, following several promising developments for the medicine maker.
Image source: Getty Images.
The European Medicines Agency's


